Literature DB >> 18458250

Bringing a research base to psychiatry.

Miriam Shuchman, Paul C Hébert, Rajendra Kale, Barbara Sibbald, Ken Flegel, Noni MacDonald.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18458250      PMCID： PMC2335202          DOI： 10.1503/cmaj.080530

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  21 in total

1.  Medicine. The NIH Roadmap.

Authors:  Elias Zerhouni
Journal:  Science       Date:  2003-10-03       Impact factor: 47.728

2.  New trial should clarify lithium use in bipolar disorder.

Authors:  John Geddes; Guy Goodwin; Jennifer Rendell; Jane Hainsworth; Emma Van der Gucht; Heather Young
Journal:  BMJ       Date:  2002-08-24

Review 3.  Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

Authors:  Stephan Heres; John Davis; Katja Maino; Elisabeth Jetzinger; Werner Kissling; Stefan Leucht
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

4.  Beyond efficacy: the STAR*D trial.

Authors:  Thomas R Insel
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

5.  Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Authors:  Lon S Schneider; Pierre N Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; T Scott Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 91.245

6.  Euphorigenic and abusive properties of modafinil.

Authors:  Stefan P Kruszewski
Journal:  Am J Psychiatry       Date:  2006-03       Impact factor: 18.112

7.  Developing the evidence for evidence-based practice.

Authors:  A John Rush
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

8.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Authors:  Peter B Jones; Thomas R E Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P Hayhurst; Robin M Murray; Alison Markwick; Shôn W Lewis
Journal:  Arch Gen Psychiatry       Date:  2006-10

9.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

10.  The case for practical clinical trials in psychiatry.

Authors:  John S March; Susan G Silva; Scott Compton; Mark Shapiro; Robert Califf; Ranga Krishnan
Journal:  Am J Psychiatry       Date:  2005-05       Impact factor: 18.112
View more
  1 in total

1.  Positive perception of pharmacogenetic testing for psychotropic medications.

Authors:  Matthew B Lanktree; Gwyneth Zai; Laura E Vanderbeek; Daniel E Giuffra; David S Smithson; Lucas B Kipp; Timothy R Dalseg; Mark Speechley; James L Kennedy
Journal:  Hum Psychopharmacol       Date:  2014-03-07       Impact factor: 1.672
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.